Therefore, it may be possible to conclude that metformin therapy, even in a relatively short time such as three months,

in patients with PCOS may cause a decrease in the ovarian Pacritinib supplier volume by decreasing intraovarian stromal androgens. The ovarian volume correlated to BMI, thus suggesting a possible relationship then between ultrasound findings and anthropometric characteristics. Furthermore, our finding that the prevalence of obesity and high androgen levels within the patients with larger ovarian volume is higher than that seen Inhibitors,research,lifescience,medical within the patients with PCOS with normal ovarian volume seems to confirm the possibility of an interaction between ovarian morphology and anthropometric characteristics. It could be hypothesized that the patients with PCOS are much more insulin resistant. This would explain the higher BMI and androgen values. Hyperandrogenism is a

key feature Inhibitors,research,lifescience,medical of PCOS. Although the adrenal gland may contribute, hyperandrogenism is principally ovarian in origin among women with a primary diagnosis of PCOS. In various populations around the world, it has been found that most women with PCOS have elevated levels of serum androgens; however, normal levels may be found in some women. Serum testosterone level is the best marker for ovarian hyperandrogenism, and DHEAS is Inhibitors,research,lifescience,medical the best adrenal marker. It is recommended that these variables be measured.2,3 In our study, most of the PCOS cases had testosterone level more than 95 percentile. After treatment, there was a significant reduction in serum testosterone concentrations, 17OHP and DHEAS similar to those reported by Nestler et Inhibitors,research,lifescience,medical al,10 Kolodziejczyk et al,13 and Bayrak et al,17 studies. There was an important

change in the menstrual pattern during metformin therapy. In Inhibitors,research,lifescience,medical agreement with the study by Morin-Papunen et al,9 up to 65% of the women with menstrual disturbances achieved more regular menstruation with metformin and two patients became pregnant. In our study, patients with PCOS had both male and female factors of infertility, and such a low rate of pregnancy may be due to these two factors. Unfortunately, we could not assess how many of the cycles were ovulatory during Dacomitinib therapy. However, spontaneous menstruation is psychologically important for the patient because it implies better ovarian function. In addition, the more frequent occurrence of menses in these patients may alleviate the known risks of endometrial hyperplasia and carcinoma in obese patients with PCOS. Conclusion The findings of the present study indicate that metformin therapy leads to comparable reduction of ovarian volume in a manner, which correlates with the degree of reduction of hyperandrogenemia. It is likely that the reduction of ovarian volume reflect a decrease in the mass of androgen producing tissues.